Utilizing Afirma GRID scores to further stratify genomic sequencing classifier–suspicious thyroid nodules

BACKGROUND: The Afirma genomic sequencing classifier (GSC) is used to stratify Bethesda category III/IV thyroid nodules into benign and suspicious groups. However, approximately 50% of GSC-suspicious nodules prove to be benign on final surgical pathology. In this study, the authors investigated whether Afirma GRID (Genomic Resource for Intelligent Discovery) data may provide additional insights into the risk stratification of cytologically indeterminate thyroid nodules. METHODS: This retrospective study included thyroid find-needle aspiration samples that had an Afirma test performed. Afirma GRID data, including Molecular Signatures Database-derived scores, were obtained, and nonparametric Mann-Whitney U tests were performed. RESULTS: In total, 178 Afirma GSC-suspicious cases were identified, of which 77 had surgical follow-up and available GRID scores. Surgical pathology revealed 23 malignancies (17 papillary thyroid carcinomas and six follicular carcinomas), 13 cases of noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP), and 41 benign cases. The invasion classifiers V1/V2, follicular mesenchymal transition scores, and radiation sensitivity scores indicated statistically significant differences between the benign versus cancer, NIFTP versus cancer, and benign + NIFTP versus cancer groups. Conversely, these four scores showed no statistically significant differences between the benign versus NIFTP and benign versus NIFTP + cancer groups. In addition, the MRPS16::TTC18 fusion was identified in a classic papillary thyroid carcinoma that has not been reported previously. CONCLUSIONS: The findings suggest that NIFTP is molecularly more similar to benign nodules than to carcinoma. The GRID scores demonstrate promising clinical utility for improved risk stratification of Afirma GSC-suspicious thyroid nodules.

Authors

Institutions

Publication Details

Journal
Cancer Cytopathology
Published
2026-11-13
DOI
https://doi.org/10.1002/cncy.70168
Primary Topic
Thyroid Cancer Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Utilizing Afirma GRID scores to further stratify genomic sequencing classifier–suspicious thyroid nodules

Shuanzeng Wei, Rajeswari Nagarathinam, Simon Sung, Taryn L Waraksa-Deutsch et al.
Cancer Cytopathology
Thyroid Cancer Diagnosis and Treatment
article

Utilizing Afirma GRID scores to further stratify genomic sequencing classifier–suspicious thyroid nodules

Shuanzeng Wei, Rajeswari Nagarathinam, Simon Sung, Taryn L Waraksa-Deutsch, Jobran Mansour, Gong Yulan, Juanita R. Kcomt, Hormoz Ehya, Min Huang
article en

Abstract

BACKGROUND: The Afirma genomic sequencing classifier (GSC) is used to stratify Bethesda category III/IV thyroid nodules into benign and suspicious groups. However, approximately 50% of GSC-suspicious nodules prove to be benign on final surgical pathology. In this study, the authors investigated whether Afirma GRID (Genomic Resource for Intelligent Discovery) data may provide additional insights into the risk stratification of cytologically indeterminate thyroid nodules. METHODS: This retrospective study included thyroid find-needle aspiration samples that had an Afirma test performed. Afirma GRID data, including Molecular Signatures Database-derived scores, were obtained, and nonparametric Mann-Whitney U tests were performed. RESULTS: In total, 178 Afirma GSC-suspicious cases were identified, of which 77 had surgical follow-up and available GRID scores. Surgical pathology revealed 23 malignancies (17 papillary thyroid carcinomas and six follicular carcinomas), 13 cases of noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP), and 41 benign cases. The invasion classifiers V1/V2, follicular mesenchymal transition scores, and radiation sensitivity scores indicated statistically significant differences between the benign versus cancer, NIFTP versus cancer, and benign + NIFTP versus cancer groups. Conversely, these four scores showed no statistically significant differences between the benign versus NIFTP and benign versus NIFTP + cancer groups. In addition, the MRPS16::TTC18 fusion was identified in a classic papillary thyroid carcinoma that has not been reported previously. CONCLUSIONS: The findings suggest that NIFTP is molecularly more similar to benign nodules than to carcinoma. The GRID scores demonstrate promising clinical utility for improved risk stratification of Afirma GSC-suspicious thyroid nodules.

Cancer CytopathologyVol. 134(12)
Fox Chase Cancer Center (US), Temple University (US)
Thyroid Cancer Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon